Accuride Corporation (NYSE:ACW), an auto components maker, posted strong Q3 results Monday, with both earnings and revenues beating the consensus of analysts polled by Capital IQ. Q3 net income totaled $1.2 million, or $0.02 per share, up from a loss of $8.4 million, or $0.18 per share in the year-ago period. Analysts were expecting a loss of $0.01 per share. Quarterly revenues jumped 18.5% year-on-year to $184 million, above the consensus of $174.4 million.Accuride CFO Greg Risch said Accuride Corporation (NYSE:ACW) is narrowing its full-year 2014 sales and adjusted EBITDA guidance to "the high end of our previous range due to continued positive momentum in our end markets," expecting sales of $690 million-$700 million compared to the previous guidance of $675 million-$700 million and adjusted EBITDA of $75 million-$80 million versus the prior guidance of $70 million-$80 million. Analysts are expecting full-year revenues of $693.4 million.Echo Therapeutics Inc (NASDAQ:ECTE) said it will present "positive" results from its study of its continuous glucose monitoring system at the annual Diabetes Technology Meeting Nov 6th to 8th. The poster, entitled "Non-Invasive Continuous Glucose Monitoring in Post-Surgical Diabetic and Non-Diabetic Intensive Care Unit Patients", will provide an expanded analysis of data collected from the multi-center clinical trial of Echo's Symphony CGM System in post-surgical diabetic and non-diabetic patients in hospital intensive care units. Echo Therapeutics Inc (NASDAQ:ECTE) gave no further details. The shares are trading within a 52-week spread of $0.39 - $4.91.Dyax Corp. (NASDAQ:DYAX) said it is expanding its ongoing phase 1b trial of DX-2930 as prevention of hereditary angioedema (HAE) attacks. Dyax Corp. (NASDAQ:DYAX) said the trial, designed to assess the safety, tolerability and pharmacokinetics of DX-2930, has had faster than anticipated enrollment rates and has decided to add two additional cohorts. Subjects will continue to be randomized to active drug or placebo in a 2:1 ratio and the dosing regimen will remain unchanged. Active drug-treated subjects in the fourth cohort will receive 400 mg of DX-2930. The dose level of the fifth cohort will be decided based upon a review of interim data."These additional cohorts will provide safety, pharmacokinetic and pharmacodynamic data which will further guide future clinical development of DX-2930," chief medical officer Burt Adelman said in a statement. "Importantly, we remain on track to report data from this study in early 2015, followed by a Phase 2 study which is also currently planned to begin in 2015."
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
